Horizon Surgical Systems recently secured $30 million in Series A funding to propel its innovative surgical robotics platform forward.
Based in Malibu, California, Horizon is focused on revolutionizing microsurgery through cutting-edge, AI-powered robotic solutions. The company intends to allocate the funds to further develop its Polaris platform, specifically tailored for eye surgeries, and aims to expedite its progression toward human clinical trials. Additionally, Horizon plans to expand its team to accelerate its growth.
The Polaris system combines advanced robotics, high-precision medical imaging, and artificial intelligence to enhance surgical performance beyond human limitations. By augmenting the surgeon’s abilities, the platform promises to redefine microsurgery with greater precision and efficiency.
Leading the investment round were ExSight Ventures and a significant corporate investor, with participation from Main Street Advisors and the University of California (UC Investments). As part of this funding, Horizon appointed Dr. Firas Rahhal from ExSight and William Link, a seasoned investor, to its board of directors.
Dr. Jean-Pierre Hubschman, the founder and CEO of Horizon, expressed gratitude for the support, emphasizing the potential impact of Polaris: “We are thrilled to have the strong backing of ExSight, Main Street Advisors, and UC Investments. Our Polaris platform stands on the brink of ushering in a new era for surgical robotics by merging augmented visualization and precise robotic control.”
Hubschman also pointed to AI’s transformative role in surgical robotics: “The rapid evolution of AI will unlock unprecedented capabilities in surgical assistance within the Polaris platform, leading to improved accuracy, efficiency, and outcomes. With the confidence shown by our investors, Horizon is swiftly moving toward human clinical trials.”
As AI continues to gain momentum in the healthcare industry, the global surgical robotics market is projected to reach $14.4 billion by 2030, with an expected compound annual growth rate (CAGR) of 17.6%, according to Allied Market Research. Horizon’s advancement in this sector could position it at the forefront of the next wave of medical innovation.
